Dosimetry in Peptide radionuclide receptor therapy: a review.

The potential of targeted therapy with radiolabeled peptides has been reported in several clinical trials. Although there have been many improvements in dose estimation, a general and reliable dosimetric approach in peptide receptor radionuclide therapy (PRRT) is still a matter of debate. This article reviews the methods for PRRT dosimetry and the results presented in the literature. Radiopharmaceutical characteristics, data processing, dosimetric outcomes, and methods to protect critical organs are reported. The biological effective dose, based on the linear quadratic model, is also described.

[1]  K. Endo,et al.  Radiation dosimetry for indium-111-pentetreotide. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  M. Cremonesi,et al.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  George Sgouros,et al.  MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  E P Krenning,et al.  Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Ryan Park,et al.  microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Xiaowei Liu,et al.  3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. , 2003, Cancer biotherapy & radiopharmaceuticals.

[7]  George Sgouros,et al.  Dosimetry of internal emitters. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  J. Eary,et al.  166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  T. Visser,et al.  Pre‐clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor‐targeted scintigraphy and radionuclide therapy , 1998, International journal of cancer.

[10]  David M. Goldenberg,et al.  Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations , 1998, European Journal of Nuclear Medicine.

[11]  M. Konijnenberg,et al.  Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? , 2003, Cancer biotherapy & radiopharmaceuticals.

[12]  A. Safavy,et al.  In vitro and in vivo evaluation of a 64Cu-labeled polyethylene glycol-bombesin conjugate. , 2004, Cancer biotherapy & radiopharmaceuticals.

[13]  Ludwig G Strauss,et al.  Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of Nuclear Medicine.

[14]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  B. Wessels,et al.  MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  R Laforest,et al.  64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  S. Adelstein,et al.  Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  E. Krenning,et al.  Candidates for peptide receptor radiotherapy today and in the future. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[19]  Raffaella Barone,et al.  Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Valkema,et al.  Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  E. Krenning,et al.  [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients , 2001, European Journal of Nuclear Medicine.

[22]  R. Valkema,et al.  Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[24]  Eva Forssell-Aronsson,et al.  Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  P. Bartenstein,et al.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  H. V. van Boven,et al.  Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  F. Forrer,et al.  Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  T. Visser,et al.  D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  R. Dale,et al.  Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. , 2004, Cancer biotherapy & radiopharmaceuticals.

[30]  R. Moncayo,et al.  111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trial , 2002 .

[31]  H. Herzog,et al.  PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  H. Herzog,et al.  Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of 86Y-DOTATOC and 111In-DTPA-octreotide , 2001, European Journal of Nuclear Medicine.

[33]  M. Cremonesi,et al.  Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  B. Bernard,et al.  Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  R. Moncayo,et al.  In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. , 2002, Seminars in nuclear medicine.

[36]  M. Béhé,et al.  Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. , 2002, Cancer biotherapy & radiopharmaceuticals.

[37]  L. Travaini,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-Octreotide: Implications for internal radiotherapy with 90Y-DOTATOC , 2000 .

[38]  S. Walrand,et al.  Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  Marion de Jong,et al.  Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  J. Siegel,et al.  Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. , 2002, Cancer biotherapy & radiopharmaceuticals.

[41]  R. Motte.  Society of Nuclear Medicine , 1981 .

[42]  E P Krenning,et al.  [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. , 2001, European journal of nuclear medicine.

[43]  K. Eckerman,et al.  Evolution and status of bone and marrow dose models. , 2002, Cancer biotherapy & radiopharmaceuticals.

[44]  C. Van de Wiele,et al.  Renal Toxicity after Radionuclide Therapy , 2004, Radiation research.

[45]  Larson,et al.  Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[46]  R. Valkema,et al.  Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. , 2002, Seminars in nuclear medicine.

[47]  G Sgouros,et al.  Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  R. Pedley,et al.  Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. , 2004, Cancer biotherapy & radiopharmaceuticals.

[49]  Raffaella Barone,et al.  Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  M. Cremonesi,et al.  A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  U. Haberkorn,et al.  (68)Ga-labeled peptides in tumor imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  J. O’Donoghue.  Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. , 2004, Cancer biotherapy & radiopharmaceuticals.

[53]  Michael G Stabin,et al.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  L. Kvols,et al.  86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[55]  E. Krenning,et al.  Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Valkema,et al.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[57]  M. Schwaiger,et al.  PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  E. Krenning,et al.  Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  F. Orsi,et al.  Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: implications for internal radiotherapy with 90Y-DOTATOC , 1999, European Journal of Nuclear Medicine.